Laman UtamaEVGN • NASDAQ
add
Evogene Ltd
Tutup sebelumnya
$1.50
Julat hari
$1.47 - $1.55
Julat tahun
$1.20 - $10.40
Permodalan pasaran
8.30J USD
Bilangan Purata
32.62K
Nisbah P/E
-
Hasil dividen
-
Pertukaran utama
NASDAQ
Berita pasaran
Kewangan
Penyata Pendapatan
Hasil
Pendapatan bersih
(USD) | Sep 2024info | Perubahan T/T |
---|---|---|
Hasil | 1.80J | -52.32% |
Perbelanjaan pengendalian | 8.17J | 9.83% |
Pendapatan bersih | -7.63J | -91.52% |
Margin untung bersih | -424.83 | -301.69% |
Pendapatan bagi setiap syer | -1.31 | -63.75% |
EBITDA | -6.83J | -93.87% |
Kadar cukai berkesan | -0.01% | — |
Kunci Kira-kira
Jumlah aset
Jumlah liabiliti
(USD) | Sep 2024info | Perubahan T/T |
---|---|---|
Pelaburan tunai dan jangka pendek | 19.95J | -46.40% |
Jumlah aset | 40.11J | -30.53% |
Jumlah liabiliti | 27.88J | 27.39% |
Jumlah ekuiti | 12.24J | — |
Syer tertunggak | 6.79J | — |
Harga kepada buku | -2.34 | — |
Pulangan pada aset | -45.97% | — |
Pulangan pada modal | -110.69% | — |
Aliran Tunai
Perubahan bersih dalam tunai
(USD) | Sep 2024info | Perubahan T/T |
---|---|---|
Pendapatan bersih | -7.63J | -91.52% |
Tunai daripada operasi | -4.93J | -14.15% |
Tunai daripada pelaburan | 2.02J | -44.68% |
Tunai daripada pembiayaan | 4.73J | -39.30% |
Perubahan bersih dalam tunai | 1.83J | -74.18% |
Aliran tunai bebas | 1.24J | 140.67% |
Perihal
Evogene is a computational biology company based in Israel. Evogene Ltd. has developed a unique computational predictive biology "CPB" platform, which leverages big data with advanced algorithms such as machine learning and other artificial intelligence, while adding a deep understanding of biology and advanced biological technologies. Evogene is using its proprietary CPB platform to computationally design and develop next-generation life-science products based upon three core components: microbes, small molecules, and genetic elements.
Evogene's computational platform allows it to substantially increase the probability of successful life-science product development, increase the efficiency and reduce the toxicity of its life-science products while reducing time and cost to development. Its strategic partners include BASF, Bayer, Corteva, ICL Group Ltd. as well as various academic and medical institutions. Wikipedia
CEO
Diasaskan
2002
Tapak web
Pekerja
142